

Index

A

- Adaptor protein 1 (AP-1)
 - binding residues, 65–66
 - structures, 65
- Alpha-synuclein
 - cholesterol-binding domain, 21–22
 - functional oligomeric ion channel formation, 23–24
 - interaction with gangliosides
 - geometry, 17–18
 - lipid binding specificity, 19
 - molecular dynamics simulations, 20
 - mutant peptides, 19
 - OH-Pi bond geometrical parameters, 17–19
 - polar/nonpolar interface, 20–21
 - SBD, 20
 - sphingolipid-binding domain, 17
 - in plasma membrane, 22–23
 - topology, 16
 - virus fusion, 24
- Amyloid channel formation, 24
- Apoptosis
 - cardiolipin
 - and Cyt c, 198
 - perturbation of, 198, 199
 - recruitment protein, 198–199
 - translocation of, 199–200
 - PS mediated extracellular signaling exposure, 183
 - receptors recognition cells, 184
 - PtdIns(3,4,5)P₃, 110–112
- ATP-binding cassette (ABC) transporters
 - InsP₆, 148
 - sphingomyelin, 8
- Auxin, 150–151, 168

B

- Barth syndrome (BTHS), 196–198, 205
- Bioactive lipid production
 - ceramide, 3–4
 - diacylglyceride, 5

C

- Calcium channel, 23–24, 146
- Cardiolipin (CL)
 - abnormalities, 198
 - apoptosis
 - and Cyt c, 198
 - perturbation of, 198, 199
 - recruitment protein, 198–199
 - translocation of, 199–200
 - bioenergetics and mitochondrial dysfunction and aging, 201
 - deficiency and ROS generation, 200–201 and supercomplexes, 200
 - biosynthesis and remodeling, 196–197
 - cellular function importance, 197–198
 - HOG stress response pathway, 202–203
 - mitochondria and vacuole, cross-talk, 203–205
 - PKC-Slt2 cell integrity pathway, 201–202
- Cellular processes
 - PA
 - cytoskeletal dynamics and organization, 169
 - inter-organelle lipid transport and membrane biogenesis, 168–169
 - physiological functions in plants, 167
 - vesicular trafficking, 168
 - PtdIns(3,4,5)P₃
 - apoptosis, 112
 - cell cycle progression, 111
 - cell growth, 111–112
 - cytoskeleton rearrangement and chemotaxis, 113–114
 - neuronal development and function, 115
 - nuclear function, 114–115
- Cell wall biogenesis, 203
- Ceramide production, 3–4
- Ceramide transfer protein (CERT), 71–72
- Cholesterol-binding domain, 21–22
- Cholesterol homeostasis, 7–8
- Class I phosphoinositide 3-kinase, 88
- Cluster of differentiation 1 (CD1), 33–34
- Cobra cardiotoxin A3 (CTX-A3), 34
- COF proteins
 - activities, 69
 - ceramide transfer protein, 71–72
 - four phosphate adaptor proteins, 73–74
 - oxysterol binding protein, 72–73
 - structural features, 69–71

D

- De novo sphingomyelin biosynthesis, 3, 4
- Detergent resistant membranes (DRM), 6
- Diacylglyceride production, 5
- Diacylglycerol (DAG), 5, 145
- Diacylglycerol kinase (DGK), 161–162
- Disabled-2 (Dab2), 30–32
- Downstream inhibitors
 - Akt inhibitors, 123–124
 - Btk inhibitors, 125, 126
 - dual PI3K/mTOR inhibitors, 124–126
 - mTOR inhibitors, 124, 125
- DrrA. *See* SidM

E

- Enzyme metabolism, Ins(1,4,5)P₃, 145–146
- Epsin related protein (EpsinR), 65–67

F

- Four phosphate adaptor proteins (FAPP), 73–74
- Functional oligomeric ion channel formation, 23–24

G

- Gangliosides-alpha-synuclein interaction
 - geometry, 17–18
 - lipid binding specificity, 19
 - molecular dynamics simulations, 20
 - mutant peptides, 19
 - OH-Pi bond geometrical parameters, 17–19
 - polar/nonpolar interface, 20–21
 - SBD, 20
 - sphingolipid-binding domain, 17
- Glycosphingolipids
 - alpha-synuclein, 16, 17, 19, 24
 - in lipid rafts, 10
- Golgi apparatus, 62, 63, 67, 68, 70–76
- Golgi localized, γ -ear-containing ARF-binding proteins (GGA)
 - binding residues, 66, 67
 - domains, 67
 - structures, 65, 67
- Golgi phosphoprotein 3 (GOLPH3)
 - binding residues, 66, 68
 - hepatitis C virus virions, 68
 - structures, 65, 68
- Golgi reassembly and stacking protein (GRASP), 65–68
- G protein-coupled receptor (GPCR)
 - PtdIns(3,4,5)P₃, 107
 - PtdIns(4,5)P₂, 88

H

- Hemostasis, 182–183
- HOG stress response pathway, 202–203

I

- Inositol hexakisphosphate (InsP₆)
 - signaling roles, 148–149
 - synthesis pathway
 - IPK1, 147
 - lipid-dependent, 147
 - microinjection, 146
 - MIPS, 148
- Inositol phosphates (InsPs)
 - gravitropism, 143
 - MIPS (*see myo*-inositol phosphate synthase enzyme (MIPS))
 - PLC, 143–144
- Inositol polyphosphate kinase 1 (IPK1), 147
- Inositol 1,4,5-trisphosphate (Ins(1,4,5)P₃) vs. DAG, 144–145
- Insulin resistance
 - ceramide, 9
 - and lipid rafts, 9–10

J

- Jasmonic acid (JA), 149

L

- Langmuir monolayer, 19, 21
- Lipid rafts
 - and cell signaling, 5–6
 - in cholesterol homeostasis, 7–8
 - effect on cholesterol efflux and inflammation, 9
 - in inflammatory signaling
 - SMS2-knockout macrophages, 7
 - toll like receptors, 6
 - tumor necrosis factor alpha, 7
 - in insulin sensitivity
 - ceramide and insulin resistance, 9
 - lipid rafts and insulin resistance, 9–10
 - plasma membrane reduction, 10
 - SPT inhibition, 9
 - sphingomyelin enriched cell membrane, 5

M

- Membrane-bound PTEN structure
 - anionic membranes, 95
 - lipid diffusion, 98
 - membrane-mimetic model systems, 92–93
 - molecular dynamics simulations, 94, 97–98
 - neutron scattering length density distribution, 95–97
 - sparsely-tethered bilayer lipid membrane, 93
 - SUMOylation sites, 92
- Mitophagy, 204
- Mitosis, 111
- Monolysocardiolipin (MLCL), 196, 197
- myo*-Inositol phosphate synthase enzyme (MIPS)
 - lack of, 150–151
 - regulation of, 149–150
 - roles of, 149

O

3-O-sulfogalactosylceramides. *See* Sulfatides
 Oxysterol binding protein 1 (OSBP1), 72–73

P

Parkinson's disease

alpha-synuclein, 16
 sulfatides, 30

Partition-defective (Par-3) proteins

regulation and function, 52–53
 structures, 45–47

Phosphatase and tensin homolog protein (PTEN)

PtdIns(4,5)P₂

anionic membranes, 95
 binding sites, 90
 cytoskeletal rearrangements, 91
 functions, 89
 membrane-mimetic model systems, 92–93
 molecular dynamics simulations, 94, 97–98
 multiple anionic lipids, 89
 neutron scattering length density distribution,
 95–97
 phosphatase activity, 90
 regulators, 91
 sparsely-tethered bilayer lipid membrane, 93
 SUMOylation sites, 92
 VSP, 92

Phosphatidic acid (PA)

cellular processes

cytoskeletal dynamics and organization, 169
 inter-organelle lipid transport and membrane
 biogenesis, 168–169
 physiological functions in plants, 167
 vesicular trafficking, 168

cellular production

DGK, 161
 PLC, 162
 PLD, 160–161

modes of action

enzymatic activity modulation, 166
 membrane structure effect, 165–166
 protein interaction (*see* Protein interactions)
 tethering proteins, 166–167

physiological processes

in animals, 169
 nutrient sensing, 171
 plant water loss, 170
 salinity and hyperosmotic stress, 170–171

production and removal of, 159–160

Phosphatidylglycerolphosphate (PGP), 196

Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂)

phosphoinositide, 86
 plasma membrane based lipid signaling, 88
 protein function and membrane recruitment, 87

PTEN

functions, 89
 membrane-bound structure (*see* Membrane-bound
 PTEN structure)

multiple anionic lipids, 89

phosphatase activity, 90

phosphoinositide gradients, 90–92

synthesis and cellular localization, 86–87

Phosphatidylinositol 4-kinases (PI4K)

type II, 61–62

type III, 62

Phosphatidylinositol-4-phosphate (PtdIns(4)P)

COF family

activities, 69

CERT, 71–72

FAPP, 73–74

OSBP1, 72–73

structural features, 69–71

Golgi pool, 63–64

metabolic pathways

mammalian enzyme and yeast homologues,
 60–61

phosphatidylinositol 4-phosphatase, 62

phosphoinositide conversion, 60

PI formation, 59–60

PI4P5K, 62–63

type III PI4K, 62

type II PI4K, 61–62

recognition systems

AP-1, 65–66

EpsinR, 66–67

GGA, 65–67

GOLPH3, 68

GRASP and golgin proteins, 65–68

protein interaction, 64–65

SidM, 68–69

vesicular trafficking

coated vesicles formation, 75–77

in sphingolipid metabolism, 74–75

TGN, 74

Phosphatidylinositol phosphates (PtdInsPs)

levels, 144

signaling, 143

Phosphatidylinositol (3,4,5)-trisphosphate

(PtdIns(3,4,5)P₃)

cellular processes control

apoptosis, 112

cell cycle progression, 111

cell growth, 111–112

cytoskeleton rearrangement and chemotaxis,
 113–114

neuronal development and function, 115

nuclear function, 114–115

discovery of, 105

disease implications

cancer, 116–118

cardiovascular disease, 119–120

diabetes, 120–122

inflammation, 118–119

fatty acid groups attachment, 106

signaling pathways

effector activation mechanisms, 110

initiation, 107–108

- Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P₃) (*cont.*)
- PH domains, 109
 - termination, 108–109
 - target signaling
 - downstream inhibitors, 123–126
 - drug resistance, 127
 - PH domain inhibitors, 126–127
 - PI3K inhibitors, 122–123
- Phosphatidylserine (PS)
- abundance of, 180
 - biosynthesis, 177
 - detection of
 - binding domains, 181–182
 - cellular membranes, 181
 - fluorescent analogues, 180
 - protein interaction, 181
 - distribution of, 179–180
 - importance of, 180
 - mediated extracellular signaling
 - apoptosis, 183–185
 - hemostasis, 182–183
 - mediated intracellular signaling
 - charge-based interactions, 185–186
 - head group recognition, 186–187
 - organellar distribution of, 179
 - production and degradation pathways, 177–178
- Phosphoinositides
- InsPs, 142
 - PDK1, 187
 - phospholipase C, 88
 - PLC, 143–144
- Phospholipase C (PLC)
- InsPs, 143–144
 - PA cellular production, 161–162
 - phosphoinositides, 143–144
- Phospholipase D (PLD), 160–161
- PICK1. *See* Protein interacting with c kinase 1 (PICK1)
- PI3K signaling pathway
- in cancer, 116–117
 - in cardiovascular disease, 119–120
 - in diabetes, 120–122
 - in inflammation, 118–119
- PKC-Slt2 cell integrity pathway, 201–202
- Plant cell signaling
- inositol phosphates (*see* Inositol phosphates (InsPs))
 - phosphoinositides (*see* Phosphoinositides)
- Plasma membrane (PM)
- alpha-synuclein, 22–23
 - PtdIns(4)P, 61–64, 74
 - PtdIns(4,5)P₂, 88
- Platelet adhesion and aggregation, sulfatides
- chemokines, 33
 - Dab2, 30–32
 - laminin, 33
 - N-PTB, 32
 - P-selectin, 30
 - thrombospondin, 33
 - vWF, 32–33
- Polychaetoid (Pyd)
- regulation and function, 52
 - structures, 45, 49–50
- Protein interacting with c kinase 1 (PICK1)
- regulation and function, 53
 - structures, 45, 48
- Protein interactions
- lipid, 43
 - PA
 - in animals, 162–164
 - charges and effect on, 162
 - electrostatic/hydrogen bond switch
 - mechanism, 165
 - in plants, 162, 163
- Protein tyrosine phosphatase Basophile (PTP-Bas), 45, 47–48
- PSD-95/Discs large/ZO-1-phosphoinositides (PDZ-PI) interactions
- classification, 50–51
 - consensus, 42
 - features, 50
 - molecular determinants
 - Par-3, 45–47
 - PICK1, 45, 48
 - PTP-Bas, 45, 47–48
 - Pyd, 45, 49–50
 - syntenin-1, 44–46
 - syntenin-2, 45, 46
 - α-syntrophin, 50
 - ZO, 45, 48–49
 - prevalence of, 43–44
 - regulation and function
 - Par-3, 52–53
 - PICK1, 53
 - Pyd, 52
 - rhophilin 2, 53
 - syntenin-1, 51
 - syntenin-2, 51–52
 - ZO, 52
 - sensorgram, 43
 - surface plasmon resonance, 43
- PS decarboxylase (PSD), 178–179
- PTP-Bas. *See* Protein tyrosine phosphatase Basophile (PTP-Bas)
- PTP1E. *See* Protein tyrosine phosphatase Basophile (PTP-Bas)
- PTPL1. *See* Protein tyrosine phosphatase Basophile (PTP-Bas)
- R**
- Reactive oxygen species (ROS)
- CL generation, 196, 197, 200
 - PA, 166, 170
 - PtdIns(3,4,5)P₃, 118
- Receptor tyrosine kinase (RTK)
- PLC activation, 88
 - PtdIns(3,4,5)P₃, 116–118, 120, 122
- Reverse cholesterol transport (RCT), 8
- Rhophilin 2, 53

S

Scaffold proteins, 41, 46, 48, 52

SidM

- binding site, 66, 68
- guanine nucleotide exchange factor activity, 68
- structures, 65, 68

SM4. *See* Sulfatides

Sparsely-tethered bilayer lipid membrane (stBLM), 93–95

Sphingolipids

- alpha-synuclein interaction with gangliosides, 17
- biosynthesis, 3
- lipid rafts, 5, 7
- PtdIns(4)P in vesicular trafficking, 74–75

Sphingomyelin (SM)

- level measurement, 3
- lipid rafts
 - and cell signaling, 5–6
 - in cholesterol homeostasis, 7–8
 - effect on cholesterol efflux and inflammation, 9
 - enriched cell membrane, 5
 - in inflammatory signaling, 6–7
 - in insulin sensitivity, 9–10
- metabolism-mediated cell signaling
 - bioactive lipid production, 3–5
 - de novo synthesis, 3, 4
- molecular structure, 2

Sphingosine kinase (SK), 187

Sulfated galactocerebrosides. *See* Sulfatides

Sulfatides

- cancer diseases, 35
- cardiovascular diseases, 35
- host-pathogen interactions, 34–35
- innate immunity and autoimmunity, 33–34
- nervous system, 29–30
- platelet adhesion and aggregation
 - chemokines, 33
 - Dab2, 30–32
 - laminin, 33
 - N-PTB, 32
 - P-selectin, 30

thrombospondin, 33

vWF, 32–33

synthesis and degradation, 28–29

Supercomplexes, 200

Syntenin-1

- C-terminal region, 46
- docking model, 44–45
- regulation and function, 51
- structures, 44–45
- supramodule, 44

Syntenin-2

- regulation and function, 51–52
- structures, 45, 46

α -Syntrophin, 50

T

Tafazzin, 197

Tamou. *See* Polychaetoid (Pyd)

Tilted peptide, 21–22

Trans-Golgi Network (TGN), 63–64, 68, 71, 74

Tuberous sclerosis complex (TSC), 111

Tumorigenesis. *See* Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P₃)

V

Virus fusion, 24

Voltage-sensitive phosphatases (VSP), 92

W

WASP verprolin homologous proteins (WAVE), 113

Wiscott-Aldrich syndrome protein (WASP), 113

Z

Zonula occludens (ZO)

- regulation and function, 52
- structures, 45, 48–49